Where does Elixir Medical Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Elixir Medical Corporation ranks #12,426 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Elixir Medical Corporation hold?

Elixir Medical Corporation holds 24 US utility patents granted between 2015 and 2024, spanning 8 technology areas.

What is Elixir Medical Corporation's Innovation Score?

Elixir Medical Corporation has an Innovation Score of 40.3 out of 100 (top 36% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Elixir Medical Corporation's patent grant rate increasing or decreasing?

Elixir Medical Corporation's recent grant velocity is -29% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Elixir Medical Corporation's patents?

Elixir Medical Corporation's patents average 35.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Elixir Medical Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Elixir Medical Corporation

Q: What technology areas does Elixir Medical Corporation focus on?

Elixir Medical Corporation's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 21 patents, ranking #308 of 3,082 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 24 granted patents across 8 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Elixir ranks #12,426 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 8 technology areas.

#12,426
of 49,997 US assignees by volume: Top 36%
by Innovation Score (40.3/100): 35.1
avg claims per patent: -29%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12426 · US Corporation #12,426 · 24 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 24 grants
UPPER-Q #12,426/49,997
PHOTO-FINISH Edge Systems
CPC-NARROW A61F · 8 areas
INNOV-PAR 40.3/100
CLAIMS-DENSE 35.1 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -29% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Edge Systems LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Elixir’s 40.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.1 pts (28%) Velocity 4.2 pts (10%) Breadth 10.0 pts (25%) Claim depth 15.0 pts (37%)

Qualcomm Incorporated · highest

85
Elixir Medical · this assignee

40
3D Lighting… · lowest

7

What this shows Elixir's Innovation Score is 40.3/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Elixir?

Each dot is one of Elixir’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Elixir’s own 35.1 claims/patent is ABOVE the 14.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Elixir vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Elixir's grants concentrate

Elixir Medical Corporation is a focused PatentsView assignee: 8 CPC subclasses with 87.5% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2018 (5 grants) versus a trough of 2 in 2015. By volume, Elixir sits between Exogenesis Corporation and Eridan Communications, Inc..

Elixir's three-year grant acceleration

Elixir Medical Corporation shows 5 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Exogenesis

24
Exposure Illumina…

24
Edge Systems

24
Elevation Lab

24
Ensign-bickford A…

24
Epic Tech

24
Ergomotion

24
Eridan Communicat…

24
Elixir Medical ◀

24

What this shows Elixir holds 24 patents at rank #12,434, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Elixir

By rank, the assignees closest to #12,434 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Elixir's primary technology class.

Elixir's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 36% higher than 64% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Elixir Medical Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	8.3%
2016	2	8.3%
2017	2	8.3%
2018	5	20.8%
2019	3	12.5%
2020	2	8.3%
2021	3	12.5%
2023	2	8.3%
2024	3	12.5%

Which technologies does Elixir Medical Corporation patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 21

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

A61B - DIAGNOSIS; SURGERY; Identification 3

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

B33Y - Additive Manufacturing, i.e. Manufacturing OF Three-dimensional [3-D] Objects BY Additive Deposition, Additive Agglomeration OR Additive Layering, e.g. BY 3-D Printing, Stereolithography OR Selective Laser Sintering 2

B23K - Soldering OR UNSOLDERING; WELDING; Cladding OR Plating BY Soldering OR WELDING; Cutting BY Applying Heat Locally, e.g. Flame CUTTING; Working BY Laser Beam 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Elixir Medical Corporation's patent record in context - here's where to go next.

Elixir Medical Corporation's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 87.5% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #12,426 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Elixir Medical Corporation against Exogenesis Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.